Creating the optimal diet: Diet can reduce the symptoms of schizophrenia

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Psiquiatría Biológica

• Publication date

  2022-05-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.psiq.2022.100364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of Curcumin in the Management of Schizophrenia: A Narrative Review

  2021cited by this paper
• The science of tea’s mood-altering magic

  2019cited by this paper
• Ketogenic diet for schizophrenia: clinical implication.

  2019cited by this paper
• Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study.

  2019cited by this paper
• Dietary patterns and physical activity in people with schizophrenia and increased waist circumference.

  2018cited by this paper
• Ketogenic diet for schizophrenia: Nutritional approach to antipsychotic treatment.

  2018cited by this paper
• The effects of the ketogenic diet on psychiatric symptomatology, weight and metabolic dysfunction in schizophrenia patients

  2018cited by this paper
• The Current Status of the Ketogenic Diet in Psychiatry

  2017cited by this paper
• Ketogenic diet in the treatment of schizoaffective disorder: Two case studies.

  2017cited by this paper
• Theanine and Caffeine Content of Infusions Prepared from Commercial Tea Samples

  2016cited by this paper
• Effect of l-theanine on glutamatergic function in patients with schizophrenia

  2015cited by this paper
• Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods

  2015cited by this paper
• Vitamin Supplementation in the Treatment of Schizophrenia

  2014cited by this paper
• Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: an 8-week, randomized, double-blind, placebo-controlled study

  2013cited by this paper
• L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.

  2011cited by this paper
• Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.

  2009cited by this paper
• Schizophrenia, gluten, and low-carbohydrate, ketogenic diets: a case report and review of the literature

  2009cited by this paper
• A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia

  2008cited by this paper
• Bicultural identity among economical migrants from three south European countries living in Switzerland. Adaptation and validation of a new psychometric instrument

  2007cited by this paper
• The gluten connection: the association between schizophrenia and celiac disease

  2006cited by this paper
• The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia

  2005cited by this paper
• Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia

  2005cited by this paper
• “Bread madness” revisited: screening for specific celiac antibodies among schizophrenia patients

  2004cited by this paper
• International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: An ecological analysis

  2004cited by this paper
• Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study.

  2003cited by this paper
• A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms.

  2002cited by this paper
• Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.

  2002cited by this paper
• Extract of Ginkgo biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia

  2002cited by this paper
• A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.

  2001cited by this paper
• Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia.

  2001cited by this paper
• Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient.

  2001cited by this paper
• EICOSAPENTAENOIC ACID TREATMENT IN SCHIZOPHRENIA ASSOCIATED WITH SYMPTOM REMISSION, NORMALISATION OF BLOOD FATTY ACIDS, REDUCED NEURONAL MEMBRANE PHOSPHOLIPID TURNOVER AND STRUCTURAL BRAIN CHANGES

  2000cited by this paper
• The unhealthy lifestyle of people with schizophrenia

  1999cited by this paper
• Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid.

  1998cited by this paper
• Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study

  1998cited by this paper
• Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation.

  1996cited by this paper
• The membrane hypothesis of schizophrenia.

  1994cited by this paper
• Vitamin C in the treatment of schizophrenia.

  1993cited by this paper
• Omega-3 fatty acid content of the US food supply.

  1992cited by this paper
• An adjunctive role for ascorbic acid in the treatment of schizophrenia?

  1987cited by this paper
• Plasma levels and urinary vitamin C excretion in schizophrenic patients.

  1986cited by this paper
• A PILOT STUDY OF THE KETOGENIC DIET IN SCHIZOPHRENIA.

  1965cited by this paper
• Ascorbic Acid in Chronic Psychiatric Patients —A Controlled Trial

  1963cited by this paper

• Latest developments on the connections between diet and most of the neuropsychiatric disorders

  2024cites this paper
• Schizophrenia is associated with severe consequences

  2023cites this paper